- Etofylline
-
- $0.00 / 1removed
-
2026-01-20
- CAS:519-37-9
- Min. Order:
- Purity: 99.53%
- Supply Ability: 10g
- Etofylline
-
- $0.00 / 1removed
-
2026-01-20
- CAS:519-37-9
- Min. Order:
- Purity: 99.53%
- Supply Ability: 10g
- Etofylline
-
- $42.00 / 500mg
-
2025-04-30
- CAS:519-37-9
- Min. Order:
- Purity: 99.53%
- Supply Ability: 10g
|
| | 7-(2-HYDROXYETHYL)THEOPHYLLINE Basic information |
| | 7-(2-HYDROXYETHYL)THEOPHYLLINE Chemical Properties |
| Melting point | 163°C | | Boiling point | 365.61°C (rough estimate) | | density | 1.3055 (rough estimate) | | refractive index | 1.6300 (estimate) | | storage temp. | Sealed in dry,Room Temperature | | solubility | H2O: Solutions may be stored for several days at 4°C.soluble | | pka | 14.48±0.10(Predicted) | | form | solid | | color | white | | Water Solubility | 2.991g/L(temperature not stated) | | Merck | 14,3878 | | InChI | 1S/C9H12N4O3/c1-11-7-6(8(15)12(2)9(11)16)13(3-4-14)5-10-7/h5,14H,3-4H2,1-2H3 | | InChIKey | NWPRCRWQMGIBOT-UHFFFAOYSA-N | | SMILES | CN1C(=O)N(C)c2ncn(CCO)c2C1=O | | CAS DataBase Reference | 519-37-9(CAS DataBase Reference) |
| Hazard Codes | Xn,Xi | | Risk Statements | 22-36/37/38 | | Safety Statements | 36-36/37-26 | | WGK Germany | 3 | | RTECS | XH5850000 | | HS Code | 2939590000 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | 7-(2-HYDROXYETHYL)THEOPHYLLINE Usage And Synthesis |
| Chemical Properties | White Solid | | Originator | Duolip,Merckle,W. Germany,1981 | | Uses | Useful synthetic intermediate in the preparation of 7-substituted xanthines. | | Uses | Cardiac analeptic;Phosphodiesterase inhibitor | | Uses | An inhibitor of 3’,5’-Cyclic Nucleotide Phosphodiesterase. Therapeutically, this compound has diuretic, muscle relaxant, bronchial dilation and CNS stimulant activities. | | Definition | ChEBI: 7-(2-hydroxyethyl)-1,3-dimethylpurine-2,6-dione is an oxopurine. | | Manufacturing Process | 107.3 g (0.5 mol) 2-(p-chlorophenoxy)isobutyric acid and 56.0 g (0.25 mol)
7-hydroxyethyltheophylline were suspended together in 250 ml xylene. They
were heated together for 15 hours in a water separator following the addition
of 1.5 g p-toluenesulfonic acid. The solution was next agitated with dilute
sodium bicarbonate solution (0.5 mol NaHCO3), water washed and evaporated
in a rotary evaporator.
The residue was then crystallized from isopropanol, yielding 58.0 g (55%
yield) of 1-(7-theophyllinyl)-2-ethyl[2-(p-chlorophenoxy)-isobutyrate] . The
compound had a melting point of 131°C to 132°C. | | Therapeutic Function | Antihyperlipidemic | | Biochem/physiol Actions | Pharmacological profile similar to theophylline. |
| | 7-(2-HYDROXYETHYL)THEOPHYLLINE Preparation Products And Raw materials |
|